China's Healthcare Industry Overview: Continued Rapid Growth Expected, Fueled by Multiple Factors Led by the Healthy China 2030 Initiative

Introduction/Executive Summary

Healthcare Statistics Snapshot and Comparison

Country/Region	China	U.S.	European Union
Demographics (2016)			
Population	1.38 billion	325 million	512 million
Share of Population Aged <u>></u> 65	10.8%	15.6%	19.0%
Life Expectancy	76.3 years (2015)	78.6 (2016)	80.6 years (2015)
Birth rate	1.30%	1.22%	1.00%
Death rate	0.71%	0.84%	1.00%
Population's Natural Growth Rate*	0.59%	0.38%	-
Healthcare Statistics (2016)			
Healthcare Spending	RMB 4.6 trillion	US\$ 3.3 trillion (RMB 22.0 trillion)	EUR 1.5 trillion (RMB 12.1 trillion)
As a % of GDP	6.23%	17.90%	7.10%
Doctors per 1,000 People	2.31	2.95	3.55 (2014)
Nurses per 1,000 People	2.54	11.3	~8.00 (2015)
Hospital beds per 1,000 People	5.37	2.75	5.15 (2015)

^{*} Birth rate less death rate

Source: Respective government's statistics

China's healthcare industry, which accounted for about 6% of the country's GDP in 2016, is expected to expand rapidly in coming years. China is vying to establish a modernized system of healthcare coverage and service delivery, and develop innovative medical products and therapies to accommodate surging demand from the world's highest population.

Rising demand for medical services in China is driven by multiple factors, including a rapidly-aging population, changing of diets and lifestyles that are unhealthy, worsening air and water pollution, abolishment of the one-child policy, growing urban population, and increasing disposal income as well as health awareness. Consequently, a significant shortage of medical services and professionals already exists in China today.

China formally laid out its vision for improving the country's healthcare capabilities through the *Healthy China 2030* Initiative. This unprecedented reform package includes commitments from over 20 government departments, outlining a blueprint to substantially upgrade China's healthcare capabilities and catapult it as an international healthcare center for the world, with a focus on innovative drug and medical device research and development, improving medical service accessibility and affordability, and enhancing the country's health awareness.

China will modernize its currently inefficient and increasingly inadequate healthcare service infrastructure. A large majority of healthcare services are delivered at the largest public hospitals in the most populated cities in China. This concentration of China's healthcare service provision has led to overburdened public hospitals, emphasizing on patient turnover above all else. A key component of *Healthy China 2030* is to encourage investment of non-public healthcare facilities so as to relieve strained state hospitals, including their personnel. Nurturing the development of the non-public healthcare service market is timely, as it caters to China's expanding middle class, which has gone to great lengths for high-quality,



IMPORTANT DISCLOSURES

Cedrus Investments Ltd. ("Cedrus") does and seeks to do business with companies covered in research reports distributed by Cedrus. Investors should consider this report as only a single factor in making their investment decision.

For additional information, please send an e-mail to information@cedrusinvestments.com

For private circulation only. This report is prepared by Cedrus and is for informational purposes only and is not intended to be, nor should it be construed to be, an advertisement or an offer or a solicitation of an offer to buy or sell any securities. The information herein, or upon which opinions have been based, has been obtained from sources believed to be reliable, but no representations, express or implied, or guarantees, can be made as to their accuracy, timeliness or completeness. The information and opinions in this report are current as of the date of the report. We do not endeavor to update any changes to the information and opinions in this report. Unless otherwise stated, all views expressed herein (including estimates or forecasts) are solely those of our research department and subject to change without notice.

The information provided in this research report is not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or clearing organization or where Cedrus is not authorized to provide such information.

This report does not take into account the specific investment objectives, financial situation, and the particular needs of any specific company that may receive it. Before acting on any information in this report, readers should consider whether it is suitable for their own particular circumstances and obtain professional advice related to their own investment needs and objectives. The value of securities mentioned in this report and income from them may go up or down, and investors may realize losses on any investments. Past performance is not a guide to future performance. Future terms are not guaranteed, and a loss of original capital may occur.

Neither the analysts responsible for this report nor any related household members are officers, directors, or advisory board members of any covered company. No one at a covered company is on the Board of Directors of Cedrus or its affiliates. The compensation for the analysts who prepare reports is determined exclusively by senior management. Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of Cedrus as a whole, of which investment banking, sales and trading are a part.

Cedrus does engage in investment banking. Cedrus does trade securities on a principal basis; however, Cedrus' research analysts are prohibited from owning securities they cover through Research Reports.

Copyright 2018 Cedrus Investments Ltd. All rights reserved. Any unauthorized use or disclosure prohibited.